Isoprenaline (Isoproterenol): Nonselective Beta Agonism, Hemodynamics and Arrhythmia Risk

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation.

Overview and classification

Isoprenaline (isoproterenol) is a synthetic catecholamine and nonselective beta-1/beta-2 adrenergic agonist, with very little clinically meaningful alpha agonist activity. Its receptor effects cause marked chronotropy/inotropy and systemic beta-2-mediated vasodilation. Its use today is mainly in closely monitored acute settings rather than routine asthma rescue treatment [1,2].

Receptor signaling and hemodynamics

Both beta-1 and beta-2 receptors signal through Gs–adenylyl cyclase–cAMP, producing increased calcium-handling activity in cardiac myocytes and relaxation of airway and peripheral vascular smooth muscle. Heart rate and myocardial oxygen demand rise; beta-2-mediated fall in systemic vascular resistance can decrease diastolic BP. Because arterial pressure depends on both cardiac output and resistance, it is misleading to assume isoprenaline necessarily raises BP in all hypotensive patients [1].

Current injectable indications

A 2026 US isoproterenol injection label lists improved hemodynamics in distributive shock or shock due to reduced cardiac output and treatment of bronchospasm occurring during anesthesia. Other electrophysiology or bradycardia uses occur under specialist protocols, but these should be labeled as context-dependent rather than universal FDA-approved first-line uses. Current standard asthma rescue care prioritizes inhaled selective beta-2 agents and ICS-containing management, not routine IV isoprenaline [2].

Administration and kinetics

The IV preparation is short acting and titrated under continuous ECG, HR, BP and perfusion monitoring. Catecholamine metabolism includes COMT and other pathways; rapid onset and offset permit close titration, but also require careful attention to infusion delivery. Infusion rates and bolus use are indication-specific, and no dose should be copied from anaphylaxis or selective beta-2 inhaler protocols [1,2].

Contraindications and critical interactions

US labeling contraindicates isoproterenol in tachycardia, ventricular arrhythmias and angina pectoris. Severe tachycardia, ectopy, myocardial ischemia, hypotension, tremor and metabolic changes can occur. Avoid simultaneous administration with epinephrine because of serious arrhythmia risk. Tricyclic antidepressants, MAO inhibitors, thyroid hormones and other sympathomimetics can potentiate effects; beta blockers oppose its actions [2].

Clinical summary

Isoprenaline provides a clear teaching model of beta-1 and beta-2 responses, but is not interchangeable with norepinephrine for all shock states or with inhaled salbutamol for ordinary asthma. Select hemodynamic support based on shock physiology, individual risks and local critical-care algorithms [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Isoproterenol hydrochloride injection: US prescribing information, revised March 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=051acbc2-7bf8-4059-e063-6394a90a115b
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *